Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
暂无分享，去创建一个
C. Porta | R. Motzer | T. Powles | T. Choueiri | T. Buchler | V. Grünwald | E. Winquist | S. Rha | P. Maroto | R. Perini | Thomas E. Hutson | M. Eto | T. Takagi | J. Burgents | M. Méndez-Vidal | J. Goh | C. Okpara | C. He | E. Kopyltsov | Sungeun Hong | J. McKenzie